loading
前日終値:
$5.63
開ける:
$5.63
24時間の取引高:
118.15K
Relative Volume:
0.25
時価総額:
$41.96M
収益:
$52.29M
当期純損益:
$-73.52M
株価収益率:
-8.2879
EPS:
-0.66
ネットキャッシュフロー:
$-100.45M
1週間 パフォーマンス:
+6.21%
1か月 パフォーマンス:
+7.68%
6か月 パフォーマンス:
-43.55%
1年 パフォーマンス:
-58.84%
1日の値動き範囲:
Value
$5.25
$5.63
1週間の範囲:
Value
$5.25
$6.10
52週間の値動き範囲:
Value
$3.61
$19.43

Precision Biosciences Inc Stock (DTIL) Company Profile

Name
名前
Precision Biosciences Inc
Name
セクター
Healthcare (1167)
Name
電話
919-314-5512
Name
住所
302 EAST PETTIGREW STREET, DURHAM, NC
Name
職員
108
Name
次回の収益日
2024-11-04
Name
最新のSEC提出書
Name
DTIL's Discussions on Twitter

DTIL を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
DTIL
Precision Biosciences Inc
5.47 41.96M 52.29M -73.52M -100.45M -0.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
480.35 123.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
723.47 79.09B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
624.94 37.97B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.20 31.74B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
259.70 27.71B 3.32B -860.46M -1.04B -8.32

Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-10 アップグレード BMO Capital Markets Market Perform → Outperform
2024-04-30 開始されました Guggenheim Buy
2022-06-17 開始されました BMO Capital Markets Outperform
2022-06-09 ダウングレード William Blair Outperform → Mkt Perform
2020-07-27 再開されました BTIG Research Buy
2020-04-03 ダウングレード Goldman Buy → Neutral
2020-03-05 開始されました Stifel Buy
2020-02-25 開始されました William Blair Outperform
2019-08-09 開始されました BTIG Research Buy
2019-07-16 開始されました H.C. Wainwright Buy
2019-04-22 開始されました Barclays Overweight
2019-04-22 開始されました Goldman Buy
2019-04-22 開始されました JP Morgan Overweight
2019-04-22 開始されました Jefferies Buy
すべてを表示

Precision Biosciences Inc (DTIL) 最新ニュース

pulisher
Feb 24, 2025

Long Term Trading Analysis for (DTIL) - Stock Traders Daily

Feb 24, 2025
pulisher
Feb 24, 2025

Can This New Gene Editing Approach Transform Duchenne Muscular Dystrophy Treatment? - StockTitan

Feb 24, 2025
pulisher
Feb 21, 2025

Precision BioSciences (DTIL) Stock Price, News & Analysis - MarketBeat

Feb 21, 2025
pulisher
Feb 20, 2025

H.C. Wainwright Maintains Buy on Precision BioSciences Stock By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 20, 2025

H.C. Wainwright Maintains Buy on Precision BioSciences Stock - Investing.com India

Feb 20, 2025
pulisher
Feb 20, 2025

Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Precision BioSciences’ (DTIL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Feb 20, 2025
pulisher
Feb 19, 2025

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate - AOL

Feb 19, 2025
pulisher
Feb 19, 2025

Breakthrough in Hepatitis B Treatment: Precision BioSciences’ New Hope - Jomfruland.net

Feb 19, 2025
pulisher
Feb 19, 2025

Precision Biosciences chief research officer sells $49,274 in stock - MSN

Feb 19, 2025
pulisher
Feb 19, 2025

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial - BioSpace

Feb 19, 2025
pulisher
Feb 19, 2025

Precision Bio stock gains on Hep B drug data (DTIL:NASDAQ) - Seeking Alpha

Feb 19, 2025
pulisher
Feb 19, 2025

Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Revolutionary Gene Therapy Achieves First-Ever ARCUS Success Against Hepatitis BWhat's Next? - StockTitan

Feb 19, 2025
pulisher
Feb 18, 2025

Precision Biosciences' general counsel sells shares worth $42,765 - MSN

Feb 18, 2025
pulisher
Feb 10, 2025

Precision BioSciences announces board member's retirement - MSN

Feb 10, 2025
pulisher
Jan 31, 2025

Precision BioSciences (DTIL) Poised for Growth with ARCUS Technology and Strategic Partnerships - HPBL

Jan 31, 2025
pulisher
Jan 29, 2025

Precision BioSciences announces board member's retirement By Investing.com - Investing.com Canada

Jan 29, 2025
pulisher
Jan 29, 2025

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs - BioSpace

Jan 29, 2025
pulisher
Jan 29, 2025

Precision BioSciences’ Cassie Gorsuch, PhD named CSO - TipRanks

Jan 29, 2025
pulisher
Jan 28, 2025

Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL

Jan 28, 2025
pulisher
Jan 26, 2025

Precision Bio rises after gene editing data: BMO upgrades (update) - MSN

Jan 26, 2025
pulisher
Jan 23, 2025

Precision Biosciences' general counsel sells shares worth $42,765 By Investing.com - Investing.com Canada

Jan 23, 2025
pulisher
Jan 23, 2025

Precision Biosciences chief research officer sells $49,274 in stock By Investing.com - Investing.com Canada

Jan 23, 2025

Precision Biosciences Inc (DTIL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$74.40
price up icon 0.53%
$22.96
price up icon 2.04%
$33.69
price down icon 0.33%
$357.50
price down icon 0.20%
$110.97
price down icon 5.14%
biotechnology ONC
$259.70
price up icon 0.47%
大文字化:     |  ボリューム (24 時間):